Boehringer Ingelheim

ESMO Preview: Highlights to Watch for This Year
BioSpace
Wed, 09/15/21 - 10:29 pm
ESMO
oncology
cancer
Gilead Sciences
Bristol Myers Squibb
Zymeworks
Amgen
Adaptimmune Therapeutics
TCR2 Therapeutics
Boehringer Ingelheim
Boehringer Ingelheim, Twist Bioscience team up for $710M+ antibody discovery collab
Fierce Biotech
Fri, 09/10/21 - 11:10 am
drug development
Boehringer Ingelheim
Twist Bioscience
antibody discovery
Could CureVac's Canceled Deal Spell Trouble for Other mRNA Cancer Vaccines?
Motley Fool
Fri, 08/27/21 - 10:54 am
CureVac
Boehringer Ingelheim
MRNA
lung cancer
vaccines
Moderna Therapeutics
BioNTech
FDA Approvals Roundup: Korsuva, Jardiance, Xarelto
RAPS.org
Fri, 08/27/21 - 10:36 am
Cara Therapeutics
Korsuva
Boehringer Ingelheim
Jardiance
Bristol Myers Squibb
Opdivo
Jardiance gets parity with Farxiga in US as FDA clears use in heart failure
Pharmaforum
Wed, 08/18/21 - 11:43 pm
Eli Lilly
Boehringer Ingelheim
FDA
diabetes
Jardiance
heart failure with reduced ejection fraction
The 7-year itch? Boehringer culls $600M cancer pact with CureVac, heaping more woe to the biotech
Fierce Biotech
Mon, 08/16/21 - 12:09 pm
CureVac
MRNA
Boehringer Ingelheim
COVID-19
vaccines
Boehringer takes alteplase to phase 3 for COVID, but drops antibody
Pharmaforum
Tue, 07/27/21 - 10:26 am
Boehringer Ingelheim
COVID-19
antibodies
alteplase
Boehringer Ingelheim latest drugmaker to limit 340B discounts
Beckers Hospital Review
Wed, 07/7/21 - 10:27 pm
Boehringer Ingelheim
340B
Eli Lilly, Boehringer Ingelheim tout pivotal heart failure win for Jardiance, potentially setting up a Novartis showdown
Endpoints
Tue, 07/6/21 - 10:52 am
Eli Lilly
Boehringer Ingelheim
heart failure
clinical trials
Jardiance
Farxiga faces first heart failure rival as EU OKs Boehringer/Lilly’s Jardiance
Pharmaforum
Wed, 06/23/21 - 10:59 am
AstraZeneca
Farxiga
heart failure
Boehringer Ingelheim
Eli Lilly
Jardiance
Boehringer, Lilly and Takeda join matchmaker PharmStars' digital health accelerator
Fierce Pharma
Wed, 06/16/21 - 11:50 am
PharmStars
digital health
accelerators
Takeda
Eli Lilly
Boehringer Ingelheim
ASCO: Boehringer, OSE offer promising glimpse of the immuno-oncology drug at the heart of their $1.4B deal
Fierce Biotech
Fri, 05/21/21 - 11:52 am
Boehringer Ingelheim
OSE Immunotherapeutics
immuno-oncology
BI 765063
ASCO 2021
The retreat of corporate venture funding?
EP Vantage
Fri, 04/23/21 - 11:02 am
funding
venture funding
venture capital
AbbVie
Amgen
Boehringer Ingelheim
Bristol Myers Squibb
Eli Lilly
GSK
JNJ
Merck
Merck KGaA
Pfizer
Roche
Sanofi
Takeda
Boehringer and MD Anderson extend KRAS cancer collaboration
Pharmaforum
Wed, 04/14/21 - 09:39 pm
Boehringer Ingelheim
MD Anderson
KRAS
cancer
Boehringer’s big cancer reveal draws near
EP Vantage
Mon, 03/29/21 - 10:27 am
Boehringer Ingelheim
AACR
cancer
oncology
KRAS
COVID-19 drives Boehringer’s R&D spend to record level in 2020
Pharmaforum
Thu, 03/25/21 - 11:49 am
Boehringer Ingelheim
R&D
COVID-19
Boehringer Ingelheim, Gubra to validate new Peptides for obesity
Pharmaceutical Business Review
Tue, 03/2/21 - 10:47 am
Boehringer Ingelheim
Gubra
peptides
obesity
JPM: Boehringer inks Enara deal to source 'dark antigens' for cancer immunotherapies
Fierce Biotech
Tue, 01/12/21 - 11:00 am
JPMHC 2021
Boehringer Ingelheim
Enara Bio
dark antigens
cancer
cancer vaccines
Boehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure label
Pharmaforum
Tue, 01/12/21 - 10:50 am
Boehringer Ingelheim
Eli Lilly
Jardiance
FDA
heart failure
fast track
Boehringer inks $1.5B NBE buyout, joining Merck in new cancer race
Fierce Biotech
Thu, 12/10/20 - 11:27 am
Boehringer Ingelheim
NBE Therapeutics
M&A
Merck
antibody-drug conjugate
ROR1

Pages